12 week study of anti-viral effect of oral UT-231B [UT 231] in non-cirrhotic hepatitis C patients who have failed interferon-based therapy.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2017
At a glance
- Drugs UT 231 (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors United Therapeutics Corporation
- 22 Oct 2005 New trial record.